Corezetta, a company specializing in healthcare big data, released a report Thursday on the top 22 claims for insurance-covered biopharmaceuticals in 2016.
According to the report, claims for Trastuzumab (Original: Herceptin) topped the list with 100.1 billion won ($94 million), a 4 percent increase from the previous year.
Other notable biopharmaceutical claims included Tripegfilgrastim (Original: Dulastin), which recorded the highest increase rate from 2015, and Peginterferon (Original: Pegasys), which marked the highest decrease rate during the same duration.
The company also noted that the growth rate of biopharmaceuticals was much higher than other chemical drugs.
By the prescription amount of biopharmaceuticals, the most frequently used indications for biopharmaceuticals were breast cancer with 96.4 billion won. Followed by ankylosing spondylitis (62.9 billion won), rheumatoid arthritis (50.1 billion won), colon cancer (49.8 billion won), Crohn's disease (39.8 billion won) and non-malignant lymphoma (32.3 billion won)
|Courtesy of Corezetta|
“In the absence of market analysis data for biopharmaceuticals, which mainly consists of in-house prescriptions, Corezetta’s PBD, a big data analysis service, is regarded as a useful big data platform service,” Corezetta CEO Yi Hong-gi said. “The company plans to provide a big data analysis system called PBD package, which shows prescription pattern analysis, concurrent disease analysis, medical practice analysis and gap analysis for biopharmaceuticals.”
The company also plans to add other drugs such as anticancer drugs, hyperlipidemia drugs, dementia drugs, and ARB drugs or diseases separately, he added.
<© Korea Biomedical Review, All rights reserved.>